MedTrace Logo

Individualized Duration of Peg-interferon/Ribavirin Treatment of Hepatitis C

NCT00910975 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2012-09-05

No results posted yet for this study

Summary

The purpose of the study is to investigate if the duration of treatment of hepatitis C with pegylated interferon and ribavirin can be individualized on the basis of how fast the hepatitis C virus concentration in the blood decreases, and if this is more cost-efficient than standard treatment.

Conditions

  • Chronic Hepatitis C, Genotype 1

Interventions

DRUG

Peg-interferon-alfa2a (Pegasys)

Peg-interferon-alfa2a 180 µg per week

DRUG

Ribavirin (Copegus)

Ribavirin 1000 or 1200 mg per day depending on if body weight is below or above 75 kg

Sponsors & Collaborators

  • Sahlgrenska University Hospital

    collaborator OTHER

  • Sodra Alvsborgs Hospital

    collaborator OTHER

  • Skaraborg Hospital

    collaborator OTHER_GOV

  • Uddevalla Hospital

    collaborator UNKNOWN

  • Skane University Hospital

    collaborator OTHER

  • Lund University Hospital

    collaborator OTHER

  • Karolinska University Hospital

    collaborator OTHER

  • Göteborg University

    lead OTHER

Principal Investigators

  • Magnus Lindh, MD, PhD · Sahlgrenska University Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-11-30
Primary Completion
2010-06-30
Completion
2011-09-30

Countries

  • Sweden

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00910975 on ClinicalTrials.gov